MINERVA NEUROSCIENCES INC (NERV)
Health Care · Clinical-stage CNS biopharmaceutical · NASDAQ
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on schizophrenia.
What MINERVA NEUROSCIENCES INC does
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatment candidates for serious psychiatric and neurological disorders. The company's lead candidate is roluperidone, which is being evaluated in clinical trials for schizophrenia and other central nervous system indications. Minerva is advancing its pipeline through clinical development with a focus on CNS disorders where there is significant unmet medical need.
Themes: neuroscience, schizophrenia drug development, CNS disorders
Fundamentals
- Price$4.84 as of 2026-08-21 close
- Market cap$231M as of 2026-08-21
- 1-year return+100.4% 2025-08-21 close $2.42 → 2026-08-21 close $4.84
- P/E129.98 as of 2026-08-24
- Net margin+4.7% as of 2026-08-24
- ROE-169.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta-0.08 as of 2026-08-24
- Last reported earnings2026-08-07 SEC EDGAR Form 8-K (Item 2.02)
How NERV compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MINERVA NEUROSCIENCES INC looks technically
MINERVA NEUROSCIENCES INC (NERV) is trading 3.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 25 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-07-06, pushing above its recent trading range. It is 61.2% below its highest point of the past year. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 3.7% below its 200-day average, the long-term trend line — a long-term downtrend | -3.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.45 | $4.45 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.03 | $5.03 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 3.85. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 25 trading days ago — a "death cross", a bearish long-term signal | 25 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 19.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($3.85 to $5.07) — its "stochastic" reading is 81 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 81.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $12.46 | $12.46 |
|---|---|---|
| From the 52-week high | it is 61.2% below its 52-week high (its highest price of the past year) | -61.2% |
| Above the 52-week low | it is 150.8% above its 52-week low (its lowest price of the past year) | +150.8% |
| Below the 52-week high | it is 61.2% below its highest point of the past year | 61.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-06, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $126.72 (set on 2016-06-02) | $126.72 |
| Given back of the 52-week move | over the past year its closes ranged ($2.03 to $8.07), and it has given back around half of its rise from last year’s low — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.14 to $4.34. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 53.5% |
| From the all-time high | it is 96.2% below its all-time high | -96.2% |
| Nearest price level | it is trading 3.7% below a resistance level at $5.02 — a price it turned at twice since 2026-03-05, most recently on 2026-04-06. Since 2024-08-21 it has 7 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.7% |
| All-time low | its lowest closing price on record is $1.15 (set on 2025-04-09) | $1.15 |
| Above the all-time low | it is 320.9% above its all-time low | +320.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 75% of it) | 25th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3684 between its high and its low — about 7.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3684 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.73 and $4.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.73 – $4.32 – $4.91 |
| Typical daily range (% of price) | its price moves about 7.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.6% |
| Stretch from the 200-day average | it is trading 0.5 daily ranges below its 200-day average price (3.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 8.8% since the prior reading | +8.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.67 toward buy |
Candlestick patterns
1
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 12.8% above the previous close 5 sessions ago and has not traded back through the level it left behind at 3.92 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +12.8% |
| Gap filled | a 2.0% gap down opened on 2026-07-23 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.7 percentage points (the stock gained 8.0% while the market gained 2.3%) | +5.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 11.8 percentage points (the stock lost 8.7% while the market gained 3.1%) | -11.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.4 percentage points (the stock lost 23.3% while the market gained 11.1%) | -34.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 79.9 percentage points (the stock gained 100.4% while the market gained 20.5%) | +79.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.53 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -12.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-07 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.65 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | +4.1% |
Price levels it has turned at before
NERV last closed at $4.84 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.02 | Resistance | 3.7% above the last close | turned there twice · 2026-03-05 to 2026-04-06 |
| $4.64 | Support | 4.2% below the last close | turned there three times · 2025-11-17 to 2026-07-23 |
| $4.27 | Support | 11.7% below the last close | turned there twice · 2025-12-16 to 2026-05-19 |
| $5.63 | Resistance | 16.4% above the last close | turned there twice · 2026-02-19 to 2026-05-21 |
| $3.98 | Support | 17.9% below the last close | turned there twice · 2026-06-25 to 2026-07-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $3.85.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$10.33 range $7.00 – $14.00; median $10.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NERV
- Consensus EPS estimate-$0.01 next reporting period, as of 2026-08-07
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of losses and uncertainty regarding future profitability","High dependence on the successful clinical development and regulatory approval of its lead candidate, roluperidone","Need for additional capital to fund operations, which may lead to dilution or restrictive financing terms"]
What changed in the latest 10-Q
AI-assisted comparison of NERV's 10-Q filed 2026-05-05 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- Newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025' (vs. 2024 in older filing)
- Newer filing shows warrant liability of $278,596,901 as of March 31, 2026 (new line item not in older filing)
- Newer filing shows marketable securities of $45,405,126 as of March 31, 2026 (new line item not in older filing)
- Newer filing shows redeemable preferred stock (Series A convertible preferred stock) of $4,961,922 (new section not in older filing)
- Newer filing shows 43,841,998 common shares outstanding as of March 31, 2026 (vs. 6,993,406 in older September 2025 filing)
- Newer filing shows changes in fair value of warrant liability of $(109,360,630) in operations (new line item not in older filing)
- Newer filing shows exercise of tranche A warrants activity (new item not in older filing)
- Newer filing shows deferred offering costs of $50,978 as of March 31, 2026
- Newer filing shows cash used in investing activities for purchase of marketable securities of $(45,294,104)
- Newer filing shows financing activity proceeds from exercise of Tranche A warrants of $1,200,000
- Removed:
- Older filing shows equipment, net of $1,360 as of September 30, 2025 (not present in newer March 31, 2026 filing)
- Older filing shows preferred stock line item (100,000,000 shares authorized, none issued) (not present in newer filing which shows Series A convertible preferred stock instead)
- Older filing shows 'Non-cash interest expense for the sale of future royalties' line item in operations (not present in newer filing)
- Older filing shows 'Other income' line item in operations of $26,579,046 for nine months 2024 (not present in newer filing)
- Reworded:
- Newer filing uses 'Part II, Item IA' for Risk Factors reference; older filing uses 'Part II, Item IA' (same wording, but year changed from 2024 to 2025)
- Newer filing balance sheet caption changed from 'Liabilities and Stockholders' Deficit' to 'Liabilities, Redeemable Preferred Stock and Stockholders' Deficit'
- Newer filing statement of operations shows '3 Months Ended March 31' periods (vs. 'Three Months Ended September 30' in older filing, reflecting different quarter reporting periods)
- Notes:
- The two filings report for different quarters (March 31, 2026 vs. September 30, 2025) and different fiscal years (2025 vs. 2024), so some differences reflect period changes rather than policy or accounting changes
- Financial data is not directly comparable due to different reporting dates and periods
- The dramatic increase in shares outstanding, warrant liabilities, and accumulated deficit likely reflects significant corporate events (e.g., merger, financing) between the two filing dates, but the provided text excerpts do not include detailed explanations of these events
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for NERV — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding NERV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 770,906
- Reported value $4,644,710
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NERV had 2,447,362 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NERV had 5.13% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.54 days to cover at the same settlement.
- Reported short interest (shares) 2,447,362
- Short interest (% of shares outstanding) 5.13%
- Prior settlement (shares) 2,420,231
- Reported change 1.12%
- Days to cover (reported) 15.54
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Acadia Pharmaceuticals (ACAD)
- Alkermes (ALKS)
- Neurocrine Biosciences (NBIX)
- Karuna Therapeutics (acquired by Bristol Myers Squibb)
- Intra-Cellular Therapies (ITCI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NERV vs…
Frequently asked questions
What does MINERVA NEUROSCIENCES INC (NERV) do?
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatment candidates for serious psychiatric and neurological disorders. The company's lead candidate is roluperidone, which is being evaluated in clinical trials for schizophrenia and other central nervous system indications. Minerva is advancing its pipeline through clinical development with a focus on CNS disorders where there is significant unmet medical need.
What sector is MINERVA NEUROSCIENCES INC (NERV) in?
MINERVA NEUROSCIENCES INC (NERV) is classified in the Health Care sector. Its industry is Clinical-stage CNS biopharmaceutical. It trades on NASDAQ.
Who are MINERVA NEUROSCIENCES INC's (NERV) competitors?
Notable peers of MINERVA NEUROSCIENCES INC (NERV) include Acadia Pharmaceuticals, Alkermes, Neurocrine Biosciences, Karuna Therapeutics (acquired by Bristol Myers Squibb) and Intra-Cellular Therapies. This peer set is informational only — not financial advice.
Is MINERVA NEUROSCIENCES INC (NERV) overbought or oversold right now?
MINERVA NEUROSCIENCES INC (NERV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NERV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.